» Articles » PMID: 35154743

Development and Comparison of 1-year Survival Models in Patients with Primary Bone Sarcomas: External Validation of a Bayesian Belief Network Model and Creation and External Validation of a New Gradient Boosting Machine Model

Overview
Journal SAGE Open Med
Publisher Sage Publications
Specialty General Medicine
Date 2022 Feb 14
PMID 35154743
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Bone sarcomas often present late with advanced stage at diagnosis and an according, varying short-term survival. In 2016, Nandra et al. generated a Bayesian belief network model for 1-year survival in patients with bone sarcomas. The purpose of this study is: (1) to externally validate the prior 1-year Bayesian belief network prediction model for survival in patients with bone sarcomas and (2) to develop a gradient boosting machine model using Nandra et al.'s cohort and evaluate whether the gradient boosting machine model outperforms the Bayesian belief network model when externally validated in an independent Danish population cohort.

Material And Methods: The training cohort comprised 3493 patients newly diagnosed with bone sarcoma from the institutional prospectively maintained database at the Royal Orthopaedic Hospital, Birmingham, UK. The validation cohort comprised 771 patients with newly diagnosed bone sarcoma included from the Danish Sarcoma Registry during January 1, 2000-June 22, 2016. We performed area under receiver operator characteristic curve analysis, Brier score and decision curve analysis to evaluate the predictive performance of the models.

Results: External validation of the Bayesian belief network 1-year prediction model demonstrated an area under receiver operator characteristic curve of 68% (95% confidence interval, 62%-73%). Area under receiver operator characteristic curve of the gradient boosting machine model demonstrated: 75% (95% confidence interval: 70%-80%), overall model performance by the Brier score was 0.09 (95% confidence interval: 0.077-0.11) and decision curve analysis demonstrated a positive net benefit for threshold probabilities above 0.5. External validation of the developed gradient boosting machine model demonstrated an area under receiver operator characteristic curve of 63% (95% confidence interval: 57%-68%), and the Brier score was 0.14 (95% confidence interval: 0.12-0.16).

Conclusion: External validation of the 1-year Bayesian belief network survival model yielded a poor outcome based on a Danish population cohort validation. We successfully developed a gradient boosting machine 1-year survival model. The gradient boosting machine did not outperform the Bayesian belief network model based on external validation in a Danish population-based cohort.

Citing Articles

Factors influencing recurrence and model development for recurrence of minimally invasive percutaneous transhepatic lithotripsy: a single-center retrospective study.

Liang Y, Zhou J, Luo Y, Su Q, Ye K, Lu F Am J Transl Res. 2024; 16(5):1740-1748.

PMID: 38883341 PMC: 11170565. DOI: 10.62347/TVRY9827.

References
1.
Simms L, Barraclough H, Govindan R . Biostatistics primer: what a clinician ought to know--prognostic and predictive factors. J Thorac Oncol. 2013; 8(6):808-13. DOI: 10.1097/JTO.0b013e318292bdcd. View

2.
Chen Y, Jia Z, Mercola D, Xie X . A gradient boosting algorithm for survival analysis via direct optimization of concordance index. Comput Math Methods Med. 2013; 2013:873595. PMC: 3853154. DOI: 10.1155/2013/873595. View

3.
Jorgensen P, Lausten G, Pedersen A . The Danish Sarcoma Database. Clin Epidemiol. 2016; 8:685-690. PMC: 5094641. DOI: 10.2147/CLEP.S99495. View

4.
Park Y, Kim H, Oh J, Lee S . The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma. Int Orthop. 2001; 24(6):307-10. PMC: 3619924. DOI: 10.1007/s002640000196. View

5.
Bielack S, Kempf-Bielack B, Delling G, Exner G, Flege S, Helmke K . Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20(3):776-90. DOI: 10.1200/JCO.2002.20.3.776. View